Y Intercept Hong Kong Ltd Acquires New Position in CONMED Corporation $CNMD

Y Intercept Hong Kong Ltd bought a new position in shares of CONMED Corporation (NYSE:CNMD) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 23,289 shares of the company’s stock, valued at approximately $1,095,000. Y Intercept Hong Kong Ltd owned about 0.08% of CONMED as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in shares of CONMED by 2.8% during the second quarter. Geode Capital Management LLC now owns 734,529 shares of the company’s stock worth $38,259,000 after purchasing an additional 19,944 shares during the last quarter. Tributary Capital Management LLC purchased a new position in CONMED during the third quarter worth about $19,549,000. Allspring Global Investments Holdings LLC boosted its stake in CONMED by 8.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 281,816 shares of the company’s stock worth $13,290,000 after buying an additional 22,330 shares during the last quarter. Invesco Ltd. boosted its stake in CONMED by 4.7% in the 2nd quarter. Invesco Ltd. now owns 129,963 shares of the company’s stock worth $6,768,000 after buying an additional 5,807 shares during the last quarter. Finally, Public Sector Pension Investment Board grew its holdings in CONMED by 7.7% in the 2nd quarter. Public Sector Pension Investment Board now owns 105,513 shares of the company’s stock valued at $5,495,000 after buying an additional 7,530 shares during the period.

Analysts Set New Price Targets

Several brokerages have recently weighed in on CNMD. Needham & Company LLC reiterated a “hold” rating on shares of CONMED in a report on Thursday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CONMED in a research note on Wednesday, January 21st. Bank of America decreased their price target on shares of CONMED from $65.00 to $52.00 and set a “neutral” rating on the stock in a report on Monday, December 8th. Wells Fargo & Company upped their price objective on CONMED from $41.00 to $42.00 and gave the stock an “equal weight” rating in a report on Thursday. Finally, Zacks Research cut CONMED from a “hold” rating to a “strong sell” rating in a report on Thursday, January 1st. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $52.83.

CONMED Price Performance

CNMD opened at $38.30 on Friday. CONMED Corporation has a 52-week low of $35.37 and a 52-week high of $74.70. The company has a 50 day moving average of $41.33 and a two-hundred day moving average of $46.33. The company has a market cap of $1.19 billion, a P/E ratio of 25.36, a P/E/G ratio of 1.66 and a beta of 0.96. The company has a quick ratio of 0.95, a current ratio of 2.10 and a debt-to-equity ratio of 0.85.

CONMED (NYSE:CNMD) last posted its earnings results on Wednesday, January 28th. The company reported $1.43 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.11. CONMED had a net margin of 3.42% and a return on equity of 14.36%. The business had revenue of $373.20 million for the quarter, compared to analyst estimates of $366.88 million. During the same quarter in the previous year, the business posted $1.34 EPS. The business’s quarterly revenue was up 7.9% on a year-over-year basis. On average, analysts expect that CONMED Corporation will post 4.35 earnings per share for the current year.

More CONMED News

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q4 results beat analysts: CONMED reported $1.43 EPS (vs. $1.32 est.) and $373.2M revenue (vs. $366.9M est.), with revenue up ~7.9% year-over-year — this is the primary catalyst cited for the stock lift. Conmed: Q4 Earnings Snapshot
• Positive Sentiment: Gross-margin and surgical/orthopedic strength highlighted: coverage notes improved gross margin and outperformance in ortho/surgical segments drove the beat and underpin management’s 2026 outlook. CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up
• Positive Sentiment: Analyst note: Wells Fargo nudged its price target up to $42 (equal-weight), signaling modest upside from current levels and validating the quarter’s credibility. Benzinga
• Positive Sentiment: Management commentary and outlook: call highlights and deep-dive pieces emphasize strategic refocusing and ortho momentum setting the tone for 2026 expectations. CNMD Q4 Deep Dive: Ortho Outperformance and Strategic Refocusing Shape 2026 Outlook
• Neutral Sentiment: Earnings call transcripts and coverage are widely available for deeper read — useful for investors wanting management detail and segment-level commentary. Earnings Call Transcript
• Neutral Sentiment: Street posture mixed: Needham reaffirmed a Hold rating, indicating some analysts remain cautious despite the beat. Benzinga
• Neutral Sentiment: Analyst models: sell-side consensus still implies moderate 2026 earnings (consensus ~4.35 EPS), so follow-through depends on sustained ortho/surgical momentum and margin trends. Compared to Estimates, Conmed (CNMD) Q4 Earnings: A Look at Key Metrics
• Negative Sentiment: Technical/valuation headwinds remain: the stock still trades well below its 52‑week high and under longer-term moving averages, so multiple expansion may be limited absent sustained execution.

CONMED Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.